secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001171843-24-001322
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q4 revenue $43.0M (+8%), net loss incl. $62.2M impairment; guides FY2024 adj. EBITDA $25-30M
--------------------------------------------------------------------------------

- Q4 revenue $43.0M (+8% YoY); net loss ($63.0M) or ($4.30)/share due to $62.2M non-cash impairment on Arthrosurface/Parcus intangibles.
- FY2023 revenue $166.7M (+7% YoY); OA Pain Management record $101.9M (+11%).
- Announces ~9% workforce reduction expected to save ~$10 million annually in 2024.
- FY2024 guidance: revenue $168-173M (+1-4%), adj. EBITDA $25-30M (margin at least 15%), up >75% at midpoint.
- Engaged Piper Sandler for strategic review, evaluating alternatives including potential sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184324001322/0001171843-24-001322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184324001322/f8k_031324.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-001322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer